New leprosy prevention combo could slash infections in high-risk communities
NCT ID NCT05597280
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This large phase 3 study tests whether a new two-dose combination of bedaquiline and rifampicin can better prevent leprosy than the current standard single-dose rifampicin. About 124,000 people living within 100 meters of a leprosy patient in the Comoros will receive either the new combo or the standard drug. The goal is to see if the new regimen reduces new leprosy cases more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPROSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fondation Damien
RECRUITINGMoroni, Comoros
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.